Isentress (raltegravir) / Merck (MSD)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
NCT00717964: Study of Raltegravir Versus Nucleotide Reverse Transcriptase Inhibitors (NRTIs) as a Backbone in HIV-Infected Subjects Switched From a Stable Boosted Protease Inhibitor (PI) Regimen

Active, not recruiting
3
34
US
Raltegravir, Isentress, current antiretroviral regimen
St. Joseph's Hospital, Florida
HIV Infections
07/11
10/11
2007-000783-25: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA™-Based Regimen - Study A

 
3
32
Europe
Kaletra (Lopinavir Ritonavir), MK-0518, KALETRA, KALETRA
Merck Sharp & Dohme de España, S.A., Merck & Co., Inc., Merck Sharp & Dohme Limited, MERCK SHARP DOHME, Merck Sharp & Dohme, Lda.
HIV Infection
 
12/08
2008-002733-70: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients

 
3
65
Europe
ISENTRESS, TRUVADA, MK-0518, ISENTRESS, TRUVADA, ISENTRESS, TRUVADA
Merck & Co., Inc., Merck & Co Inc.,, Merck & Co. Inc., Laboratoires Merck Sharp & Dhome-Chibret, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK & CO., INC., MSD BV
HIV infection
 
05/11
2010-018878-21: A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to raltegravir

Ongoing
3
40
Europe
Isentress, Truvada (tenofovir disoproxil/emtricitabine), Isentress, Truvada, Isentress, Truvada
St Stephen\'s AIDS Trust
HIV
 
 
2019-001961-34: ANRS 173 ALTAR (ALlégement du Traitement AntiRétroviral) ANRS 173 ALTAR (ALlégement du Traitement AntiRétroviral)

Not yet recruiting
3
360
Europe
Film-coated tablet, , VIREAD or Tenofovir disoproxil fumarate (generic drug), STRIBILD 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg of tenofovir disoproxil fumarate or 136 mg of tenofovir), BIKTARVY bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide., ISENTRESS, TIVICAY, DESCOVY 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide, GENVOYA 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide, EPIVIR or Lamivudine (generic drugs), TRUVADA or Emtricitabine and tenofovir disoproxil fumarate (Generic drug)
INSERM ANRS, ANRS
Hiv Infection Infection par le VIH, Hiv Infection Infection par le VIH, Diseases [C] - Virus Diseases [C02]
 
 

Download Options